Kisqali 600 MG daily dose UU 63S
Ended Awarded Last action
- Contract number
- SPE2DR26FM2QW
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,280
Award facts
- Contract value 100% obligated
- $12,280.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12.28K delivery order to AmerisourceBergen Drug Corp for Kisqali 600 mg daily dose tablets (63-count units) on January 16, 2026, with completion targeted for February 9, 2026. This is a firm fixed-price, non-set-aside contract with performance in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s large Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to $999.999B through December 31, 2031, which serves as the primary vehicle for supplying comprehensive pharmaceutical products and medical supplies to military healthcare programs globally.
Kisqali (ribociclib) is an oncology medication used in breast cancer treatment, reflecting the breadth of specialized pharmaceutical commodities that AmerisourceBergen delivers to federal military and veteran healthcare systems under its DLA framework agreement. As a major pharmaceutical distributor, AmerisourceBergen maintains a significant role in the federal medical supply chain, fulfilling delivery orders across multiple therapeutic domains including specialty medications, brand-name and generic drugs, vaccines, and medical devices. This particular order demonstrates the company's continued capability to supply critical cancer therapeutics to support Defense Health Agency operations and other federal medical institutions.
Quick answers
Who was awarded contract SPE2DR26FM2QW?
SPE2DR26FM2QW was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 16, 2026.
How much is contract SPE2DR26FM2QW worth?
The government has obligated $12,280 on SPE2DR26FM2QW.
Is contract SPE2DR26FM2QW an order under another contract?
Yes. SPE2DR26FM2QW is a delivery order under SPE2DR25D3501, an indefinite delivery contract.
Was contract SPE2DR26FM2QW competed?
The extent of competition for SPE2DR26FM2QW was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award